# Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing

> **NCT00907296** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 402 (actual)

## Conditions studied

- Fracture Healing

## Interventions

- **BIOLOGICAL:** Romosozumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00907296
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-02
- **Primary completion:** 2012-03-06
- **Final completion:** 2013-05-10
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2022-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00907296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00907296, "Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00907296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*